Back to Search Start Over

[Bilateral AION after the combined therapy of hepatitis C with PEG-interferon alpha2B and ribavirin].

Authors :
Kirchhoff A
Kirchhoff U
Lafrenz M
Guthoff R
Source :
Klinische Monatsblatter fur Augenheilkunde [Klin Monbl Augenheilkd] 2004 Sep; Vol. 221 (9), pp. 791-3.
Publication Year :
2004

Abstract

Introduction: Chronic hepatitis C-therapy is limited to the combined use of PEG-ylated interferons and ribavirin. Side effects of this therapy include retinal changes that manifest with bleeding, cotton wool spots and/or thrombosis.<br />Patient: A 51-year-old man presented with a sudden decrease of visual acuity. Chronic hepatitis C was known for the duration of 6 months and treated for 3 months with a combined therapy of PEG-interferon alpha2B and ribavirin. A sudden visual loss occurred in the right eye and bilateral visual field defects were detected. Ophthalmoscopic examination revealed bilateral papilloedema. After withdrawal of PEG-interferon alpha2B and ribavirin, a standard haemodilution therapy was started without functional improvement. After papilloedema regression, a beginning secondary atrophy of the optic nerve was diagnosed bilaterally. Vision did not improve.<br />Conclusion: The ocular side effects of combined hepatitis C therapy with PEG-interferon alpha2B and ribavirin range from mild retinal changes to severely impaired vision. Treatment should be carried out in co-operation with an ophthalmologist. With respect to the uncertain effectiveness of hepatitis C therapy with interferon alpha2B and ribavirin, therapy should be stopped as soon as severe ophthalmological complications occur.

Details

Language :
German
ISSN :
0023-2165
Volume :
221
Issue :
9
Database :
MEDLINE
Journal :
Klinische Monatsblatter fur Augenheilkunde
Publication Type :
Academic Journal
Accession number :
15459850
Full Text :
https://doi.org/10.1055/s-2004-813607